

Abstract

The present invention relates to the utilization of a
10 compound capable of antagonizing at least partially the
oncogenic activity of the protein Mdm2 for the preparation of a
pharmaceutical composition intended more particularly to a
treatment of cancers with no p53 context. It further relates to
the viral vector comprising a nucleic acid sequence coding for a
15 compound capable of inhibiting at least partially the oncogenic
activity of the protein Mdm2, and to a corresponding
pharmaceutical composition.